On the other hand, strict government guidelines and lack of knowledge about detailed examination are likely to have a negative impact on the growth of the market in the coming years.
According to our new market research study on “Human Microbiome Market to 2027 – COVID-19 Impact and Global Analysis – by Product, Disease, Application, and Geography,” the market is expected to reach US$ 4,542.67 million by 2027 from US$ 2,620.88 million in 2019. Increasing focus on human microbiome therapies and growing technological advancements in metagenomics and next-generation sequencing are expected to boost the growth of the market. On the other hand, strict government guidelines and lack of knowledge about detailed examination are likely to have a negative impact on the growth of the market in the coming years.
The growth of the market is driven by the factors, such as increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing. However, strict government guidelines and the lack of knowledge and detailed examination are likely to have a negative impact on the growth of the market in the coming years.
Request for sample PDF Brochure at: https://www.theinsightpartners.com/sample/TIPBT00002233/
Enterome; Rebiotix Inc.; Yakult Honsha Co., Ltd.; Osel Inc.; Vedanta Biosciences, Inc.; Synthetic Biologics, Inc.; DuPont; BiomX Ltd; MaaT Pharma; Eligo Bioscience; Merck & Co., Inc.; AOBiome LLC; Kaleido; and Seres Therapeutics are among the leading companies operating in the human microbiome market.
Several players have observed good demand for human microbiome based products during the initial period of COVID-19, particularly from the food & beverages industry. In addition, researchers are studying the correlation between gut bacteria and COVID-19. Many researchers have showcased gut bacteria’s implication in different health conditions, from type 2 diabetes to depression. However, the obstacles in supply chains and distribution networks resulting in unavailability of human microbiome based products in various parts of the world are likely to hamper the growth of the market in 2020.
Fecal microbiota transplantation (FMT) has emerged as an effective treatment for C. difficile infection (CDI). The microbiota have important roles in the function of gastrointestinal tract and other aspects of human physiology. There has been rise in interest in studying FMT for other clinical indications. The US Food and Drug Administration (FDA) has classified human stool as a biological agent and determined that the use of human stool in FMT therapy and other research must be regulated for the insurance of patient safety. To use FMT in the treatment of recurrent Clostridium difficile infection, an investigational new drug permit is not required, but it is strongly encouraged and may ultimately be required. In March 2016, the US FDA released clarifying guidance and the draft of Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements that focused on the use of Fecal Microbiota for Transplantation to Treat Clostridium difficile infection when the patients is not responsive to standard therapies. Some of the available data suggests that the use of fecal microbiota for the restoration of intestinal flora may be an effective therapy in the management of refractory C. difficile infection. However, the efficiency and protection profiles of this intervention have not yet been fully evaluated in controlled clinical trials. Thus, the investigational drug requirement plays a vital role in the application of microbiome, thereby giving it an array of opportunities in future.
Over the past few decades, human microbiome is related to lifestyle diseases, such as cancer, diabetes, and obesity. Changes in lifestyles and societal norms influence the microbiome at each stage of life. Altering the human microbiome can help in eliminating such lifestyle diseases. As per the World health organization in 2016, 13% of the world population (adults) were obese. According to the “The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation” published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ, whose composition and functionality contribute to the development of obesity. Therefore, fecal/gut microbiome transplantation (GMT), which involves the transfer of feces from a healthy donor to the patient, is a potential treatment for obesity. Diabetes is one of the largest global health emergencies of the 21st century. Each year more and more people live with this condition, which can result in life-changing complications. According to the International Diabetes Federation (IDF), in 2017, number of people with diabetes in North America was approximately 46 million, which is expected to grow to 62 million in 2045. The increase in prevalence of the disease is likely to be around 35% during the forecast period. Thus, by altering the microbiome by prebiotics or probiotics, fecal transplantation diabetes can be prevented as well as treated. Thus, increasing incidence of chronic lifestyle diseases is likely to drive the for human microbiome market during the forecast period.
Based on product, the human microbiome market is segmented into probiotics, foods, prebiotics, medical foods, diagnostic devices, drugs, and supplements. In 2019, the probiotics segment held the largest share of the human microbiome market. This segment is expected to dominate the market in 2027 owing to increasing health concerns; growing awareness regarding the relation of nutrition, diet, and health; and increasing probiotics market penetration in dairy and other foods. Furthermore, the prebiotics segment is anticipated to witness the fastest growth rate during the forecast period.
Buy Complete Report of Human Microbiome Market Study at: https://www.theinsightpartners.com/buy/TIPBT00002233/
Related Reports:
Human Microbiome Sequencing Technology Market Forecast to 2028
Microbiome Sequencing Services Market Forecast to 2028
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876